Category: Parkinson's Disease (Other)
Objective: To evaluate the clinical efficacy, care giver satisfaction and cost-effectiveness in the clinical management of Parkinson’s Disease (PD) compared to conventional care over 12 months as part of the EmPARK-PKG project
Background: Parkinson’s disease (PD) is a progressive neurodegenerative disorder that requires ongoing caregiver support and can lead to frequent hospital admissions as the disease advances. Home-based wearable sensor monitoring provides a detailed and continuous record of patient symptoms, potentially improving disease management, increasing cost-effectiveness, and alleviating caregiver burden.
Method: we analysed 50 ( EMPARK) vs 45 ( conventional) patients baseline to 12 months looking ar healthcare utilisation, clinical outcomes, Care giver burden and quality-adjusted life years (QALYs) to determine financial and health impacts of PKG use. A Markov model was constructed to simulate transitions between three health states (Mild, Moderate, Severe) over 20 cycles for both the Conventional and EmPARK groups. All statistical analyses were conducted using IBM SPSS version 29, with statistical significance at p < 0.05. Descriptive statistics, including means, standard deviations, medians, and interquartile ranges (IQR), were calculated for key variables such as costs and quality-adjusted life years (QALYs).
Results: The PKG implementation showed fewer hospitalisations, and lower healthcare costs also showed an improvement in caregiver burden. Cost-effectiveness: initial costs for the PKG implementation were high, but significant cost reductions were achieved in 12 months. The ICER was notably negative (-AED 2,664,071 per QALY gained in motor scores; -AED 819,715 per QALY gained in PDQ scores), indicating substantial cost savings and health benefits
Conclusion: These results suggest that PKG offers a clinically effective, cost-saving, and reduction-in caregiver burden alternative for PD management, supporting continuous symptom monitoring and proactive treatment adjustments
To cite this abstract in AMA style:
V. Metta, M. Qamar, H. Benamer, T. Loney, G. Goyal, R. Dhamija, P. Kukle, R. Borgohain, R. Mridula, H. Hussain, A. Nalarakettil, R. Chaudhuri. Clinical Efficacy, Cost Effectiveness, and Caregiver Satisfaction of the Application of Parkinson’s KinetiGraph (PKG) in Clinical Practice versus Standard Care – a 12-month Longitudinal Analysis Part of the EmPARK-PKG Project [abstract]. Mov Disord. 2025; 40 (suppl 1). https://www.mdsabstracts.org/abstract/clinical-efficacy-cost-effectiveness-and-caregiver-satisfaction-of-the-application-of-parkinsons-kinetigraph-pkg-in-clinical-practice-versus-standard-care-a-12-month-longitudinal-analy/. Accessed October 5, 2025.« Back to 2025 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/clinical-efficacy-cost-effectiveness-and-caregiver-satisfaction-of-the-application-of-parkinsons-kinetigraph-pkg-in-clinical-practice-versus-standard-care-a-12-month-longitudinal-analy/